| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 677.96 KB | Adobe PDF |
Orientador(es)
Resumo(s)
The membrane receptor tyrosine kinases (RTKs), possess both extracellular and intracellular domains and selectively catalyze the phosphorylation of tyrosine hydroxyl groups in response to binding of certain extracellular growth factors. RTK signalling pathways are normally highly regulated, yet their over-activation has been shown to promote the growth, survival, and metastasis of cancer cells, and has been associated with the progression of various human cancers. Recently some thieno[3,2-c]pyridine 1,3-diarylurea derivatives were prepared as VEGFR-2 (vascular endothelium growth factor receptor-2) inhibitors.1 Here we present the synthesis of methyl 3-amino-6-[4 or 3 or 2-(3-arylureido)phenyl]thieno[3,2-b]pyridine-2-carboxylates 2 by reaction of the methyl 3-amino-6-(4 or 3 or 2-aminophenyl)thieno[3,2-b]pyridine-2-carboxylates 1, synthesized earlier by our group,2 with arylisocyanates
Descrição
Palavras-chave
Contexto Educativo
Citação
Peixoto, Daniela; Dias, Sofia; Froufe, Hugo; Abreu, Rui M.V.; Ferreira, Isabel C.F.R.; Queiroz, Maria-João R.P. (2011). Methyl 3-amino-6-[4 or 3 or 2-(3-arylureido)phenyl]thieno[3,2-b]pyridine-2-carboxylates: synthesis and molecular modelling studies using VEGFR-2. In 2nd Iberic Meeting on Medicinal Chemistry: G Protein-Coupled Receptors and Enzymes in Drug Discovery. Porto